Uterine myoma. Leiomyoma of uterus, unspecified
Conditions
Interventions
Intervention 1: First intervention group will be received Letrozole tab (2.5 mg once day, orally, Femara, Novartis, Basel Switzerland) for 3 months from the first day of the menstrual cycle. Intervent
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 20-45 years old women with uterine myoma (size 3 to 8 cm) presenting bleeding and pelvic pain.
Exclusion criteria
Exclusion criteria: Patients who have a hemoglobin level of 9 grams per deciliter or higher and consume iron pills. Patients over the age of 45 years. Patients with basal myoma who have received hormonal treatment in the past three months. Patients with kidney and/or liver disease. Consumers of antipsychotic drugs. Patients with a history of drug treatment or surgery for uterine myoma with severe bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine size. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Sonography.;Uterine bleeding amount. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: menstrual cup.;Uterine myoma size. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lactate Dehydrogenase (LDH). Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Lactate Dehydrogenase (LDH) Assay Kit (Colorimetric).;Serum iron. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Serum Iron Assay Kit (Colorimetric).;Hemoglobin. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Hemiglobincyanide method.;Possible clinical side effects of the drug (Including hot flashes, headaches, vaginal dryness and vomiting, etc.). Timepoint: During and after 12 weeks of treatment. Method of measurement: Clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNooshin Modaber
Iran University of Medical Sciences
Outcome results
None listed